Celldex Therapeutics is dropping its barzolvolimab program in eczema after the monoclonal antibody failed to meet a Phase 2 endpoint. The company reported the therapy did not reduce itching versus placebo, according to the mid-stage results. The decision underscores the clinical and commercial difficulty of inflammatory skin targets that have struggled to translate into durable symptom relief in controlled trials. Celldex’s pullback also reflects how quickly dermatology pipelines can narrow once pivotal tolerability or efficacy signals miss. Investors will likely refocus on Celldex’s remaining assets and the company’s near-term strategy for rebalancing its immunology portfolio after the setback.